EYEN Archives - BioTuesdays

Developments

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

Eyenovia (NASDAQ:EYEN) entered an agreement with Taiwan-based Formosa Pharmaceuticals (TWO:6838) to acquire the exclusive U.S. rights to distribute and sell Formosa’s APP13007 (clobetasol propionate ophthalmic...

August 16, 2023

Markets

HCW starts Eyenovia at buy; PT $12

H.C. Wainwright launched coverage of Eyenovia (NASDAQ:EYEN) with a “buy” rating and $12 price target. The stock closed at $2.15 on Oct. 4. Eyenovia is developing ophthalmic therapeutics based on the company’s microdose...

October 5, 2022

Feature

Arctic Vision sees busy ophthalmic business development in 2021

After closing four licensing deals for five assets in 2020 and so far in 2021, including its latest deal in early June, closely-held Arctic Vision, a leading player in China’s ophthalmology market, has no plans to slow...

June 22, 2021

Developments

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Eyenovia (NASDAQ:EYEN) announced that the first set of patients has been enrolled in the company’s Phase 3 VISION-1 study of MicroLine, a proprietary pilocarpine formulation delivered via its Optejet dispenser for the...

December 16, 2020

Feature

Eyenovia micro-array print therapeutics targeting various ophthalmic indications

Eyenovia (NASDAQ:EYEN) is using its unique microdose drug delivery technology, Optejet, to build a late-stage pipeline of ophthalmic therapeutics. “We have three late-stage programs for three major indications that we...

May 5, 2020

Markets

Ladenburg cuts Eyenovia PT to $19 from $30

Ladenburg Thalmann lowered its price target for Eyenovia (NASDAQ:EYEN) to $19 from $30, but reiterated its “buy” rating, reflecting dilution associated with a recent financing and anticipated additional dilution...

March 26, 2020

Developments

Eyenovia posts positive results from second MicroStat Phase 3 trial

Eyenovia (NASDAQ:EYEN) reported positive results from its second Phase 3 study, MIST-2, evaluating the safety and efficacy of its MicroStat fixed-combination formulation for the treatment of pharmacologic mydriasis, or...

February 25, 2019

Tag - EYEN

Eyenovia acquires U.S. rights for ocular asset from Formosa Pharmaceuticals

HCW starts Eyenovia at buy; PT $12

Arctic Vision sees busy ophthalmic business development in 2021

First patients enrolled in Eyenovia Phase 3 MicroLine study for presbyopia

Eyenovia micro-array print therapeutics targeting various ophthalmic indications

Ladenburg cuts Eyenovia PT to $19 from $30

Eyenovia posts positive results from second MicroStat Phase 3 trial

General

More